September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

James P. Crowley: MDS vs MPN – Understanding the Difference

James P. Crowley/www.researchgate.net

Sep 4, 2026, 12:52

James P. Crowley: MDS vs MPN – Understanding the Difference

James P. Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared a post on LinkedIn, adding:

“In order to understand myelodysplastic/myeloproliferative neoplasms (MDS/MPN) disease overlap, it’s important to first differentiate between myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

MDS represents a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.

Cells look abnormal under the microscope and those with this disease tend to have low blood cell counts.

Some of the symptoms of MDS include infection, anemia, bleeding, and bruising.

These problems are largely the result of abnormal blood cell numbers or function.

Some patients diagnosed with MDS will eventually develop an acute leukemia.

The risk of this happening is not the same for all patients with MDS.

There are several important features of MDS that help physicians predict whether a patient’s MDS is more or less likely to transform into an acute leukemia, however, these tools are imperfect.

Myeloproliferative neoplasms (MPNs) are a group of diseases that affect normal blood cell production in the bone marrow.

Generally, MPNs are characterized by an overproduction of blood cells, also known as proliferation.”

Other posts featuring James P. Crowley on Hemostasis Today.